The impact of chemotherapy dose adjustment and delay in patients with leukemias and lymphomas who exercise
DOI:
https://doi.org/10.12775/QS.2024.21.51462Keywords
Chemotherapy, delays, oncology, physical activity, leukemia, lymphomaAbstract
This review addresses the critical challenge of leukemia and lymphoma, delving into the epidemiology, treatment adherence, impact of physical activity, and the pressing need for more effective chemotherapy protocols. The purpose is to synthesize current knowledge, highlight existing gaps, and emphasize the importance of innovation in patient care strategies. Epidemiological data show variability in incidence rates and underscore the roles age, genetics, and lifestyle play in disease risk and progression. These insights are vital for effective prevention and timely intervention.
The focus of the discussion revolves around the development of chemotherapy protocols. Tailoring these to the individual's genetic and cancer profile can lead to significant gains in efficacy and minimize unwanted side effects, crucially improving patient quality of life and compliance.
Treatment adherence is fundamental to successful outcomes, requiring multifaceted support strategies. Education, side-effect management, and addressing care barriers are pivotal in ensuring patients fully benefit from therapy. Personalization in chemotherapy protocol development is a current focus, aiming to maximize efficacy while minimizing side effects to improve quality of life and survival. The conclusion advocates for an integrated approach combining research and clinical practice to cater to the biological intricacies of both the malignancy and the patient. Progress in these areas proclaims a future where personalized, effective, and compassionate cancer treatment is the norm, pushing us closer to the goal of transforming cancer into a manageable condition.
References
M. Burns et al.. "Identification of prognostic factors in childhood T‐cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05‐001 and 11‐001". Pediatric Blood & Cancer. vol. 68. no. 1. Oct. 2020. https://doi.org/10.1002/pbc.28719.
P. A. Thompson, H. M. Kantarjian and J. E. Cortés. "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". SYMPOSIUM ON NEOPLASTIC HEMATOLOGY AND MEDICAL ONCOLOGY. vol. 90. no. 10. pp. 1440-1454. Oct. 2015. 10.1016/j.mayocp.2015.08.010.
R. L. Siegel, K. D. Miller, N. S. Wagle and A. Jemal. "Cancer statistics, 2023". CA: A Cancer Journal for Clinicians. vol. 73. no. 3. pp. 233-254. Mar. 2023. https://doi.org/10.3322/caac.21772.
A. Bonaventure et al.. "Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries". The lancet. Haematology. vol. 4. no. 5. pp. 202-217. Apr. 2017. https://doi.org/10.1016/S2352-3026(17)30052-2.
T. Terwilliger and M. Abdul‐Hay. "Acute lymphoblastic leukemia: a comprehensive review and 2017 update". Blood cancer journal. vol. 7. no. 6. pp. 577-577. Jun. 2017. https://doi.org/10.1038/bcj.2017.53.
M. Belson, B. Kingsley and A. K. Holmes. "Risk Factors for Acute Leukemia in Children: A Review". Environmental health perspectives. vol. 115. no. 1. pp. 138-145. Jan. 2007. https://doi.org/10.1289/ehp.9023.
"BCR-ABL1 in leukemia: Disguise master outplays riding shotgu... : Journal of Cancer Research and Therapeutics". Journal of Cancer Research and Therapeutics. vol. 9. no. 1. pp. 610. Nov. 2013. 10.4103/0973-1482.110339.
M. Du et al.. "The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030". Journal of Oncology. vol. 2022. pp. 1-14. Apr. 2022. 10.1155/2022/1612702.
S. M. Ansell. "Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management". American Journal of Hematology. vol. 93. no. 5. pp. 704-715. Apr. 2018. 10.1002/ajh.25071.
J. Kuruvilla. "Standard therapy of advanced Hodgkin lymphoma". American Society of Hematology. vol. 2009. no. 1. pp. 497-506. Jan. 2009. 10.1182/asheducation-2009.1.497.
K. C. Thandra, A. Barsouk, K. Saginala, S. Padala, A. Barsouk and P. Rawla. "Epidemiology of Non-Hodgkin’s Lymphoma". medical sciences. vol. 9. no. 5. Jan. 2021. https://doi.org/10.3390/medsci9010005.
P. Boffetta. "I. Epidemiology of adult non-Hodgkin lymphoma". EDUCATIONAL BOOK. vol. 22. no. 4. pp. 27-31. Jun. 2011.
M. Al-Hamadani, T. M. Habermann, J. R. Cerhan, W. R. Macon, M. J. Maurer and R. S. Go. "Non-Hodgkin lymphoma subtype distribution,geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer DataBase from 1998 to 2011". American Journal of Hematology. vol. 90. no. 9. pp. 790-795. Jun. 2015.
A. Caley and R. J. Frcp. "The principles of cancer treatment by chemotherapy". Surgery. vol. 30. no. 4. pp. 186-190. Apr. 2012.
J. M. Goldman. "Prospects for cure in leukaemia.". Journal of Clinical Pathology. vol. 40. no. 9. pp. 985-994. Sep. 1987. 10.1136/jcp.40.9.985.
V. W. Ing. "The Etiology and Management of Leukopenia". Can Fam Physician. vol. 30. pp. 1835–1839. Sep. 1984.
P. A. Brown. "Treatment of infant leukemias: challenge and promise". Hematology Am Soc Hematol Educ Program. vol. 2013. no. 1. pp. 596-600. Dec. 2013. 10.1182/asheducation-2013.1.596.
G. H. Lyman, E. Abella and R. Pettengell. "Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.". Critical Reviews in Oncology/Hematology. vol. 90. no. 3. pp. 190-199. Jun. 2014.
J. Kwak, J. Halpern and R. Olshen. "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.". Journal of Clinical Oncology. vol. 8. no. 6. pp. 963-977. Jun. 1990.
R. Epelbaum, N. Haim and M. Ben-Shahar. "Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphom". Israel Journal of Medical Sciences. vol. 24. no. 9. pp. 533-538. Sep. 1988.
G. H. Lyman, J. Crawford, D. Tomita, S. Whittaker and D. C. Dale. "Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma". Leukemia & Lymphoma. vol. 57. no. 2. pp. 283-290. Jul. 2015. https://doi.org/10.3109/10428194.2015.1045894.
A. Puła, M. Zdunek, K. Michalczyk, M. Cichosz and W. Młynarski. "Chemotherapy delays in children with acute lymphoblastic leukemia might influence the outcome of treatment". Acta Haematologica Polonica. vol. 53. no. 2. pp. 141-148. Apr. 2022. 10.5603/ahp.a2022.0007.
E. Bowhay-Carnes, C. Fountzilas, M. J. Martinez, B. Konkel, B. Stormes and A. B. Karnad. "Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure". blood. vol. 126. no. 23. pp. 5092. Dec. 2015.
G. Rodrigues and M. Sanatani. "Age and comorbidity considerations related to radiotherapy and chemotherapy administration.". Seminars in Radiation Oncology. vol. 22. no. 4. pp. 277-283. Oct. 2012.
Wonders KY, Schmitz KH, Harness J. Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment. Integrative Cancer Therapies. Vol. 22. April 19, 2023. https://doi.org/10.1177/15347354231168368
T. Bao, J. Hopkins and S. Kimmel. "Use of acupuncture in the control of chemotherapy-induced nausea and vomiting.". Journal of the National Comprehensive Cancer Network. vol. 7. no. 5. pp. 606-612. May. 2009.
L. E. Carlson and B. D. Bultz. "Benefits of psychosocial oncology care: Improved quality of life and medical cost offset". Health and Quality of Life Outcomes. vol. 1. no. 8. Jan. 2003.
D. B. Mitschke. "Cancer in the Family: Review of the Psychosocial Perspectives of Patients and Family Members". Journal of Family Social Work. vol. 11. no. 2. pp. 166-184 . Jul. 2008. https://doi.org/10.1080/10522150802175159.
M. C. Politi, J. L. Studts and J. Hayslip. "Shared Decision Making in Oncology Practice: What Do Oncologists Need to Know?". The oncologist. vol. 17. no. 1. pp. 91-100. Jan. 2012. 10.1634/theoncologist.2011-0261.
E. Pefani, N. Panoskaltsis, A. Mantalaris, M. C. Georgiadis and E. N. Pistikopoulos. "Design of optimal patient-specific chemotherapy protocols for the treatment of acute myeloid leukemia (AML)". Computers & Chemical Engineering. vol. 57. pp. 187-195. Oct. 2013. https://doi.org/10.1016/j.compchemeng.2013.02.003.
E. Frei and G. P. Canellos. "Dose: A critical factor in cancer chemotherapy". The American Journal of Medicine. vol. 69. no. 4. pp. 585-594. Oct. 1980. 10.1016/0002-9343(80)90472-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Bartłomiej Szymański, Szymon Piaszczyński, Kacper Płeska, Joanna Wojtania, Michał Łepik, Zofia Uszok, Krzysztof Rosiak, Kacper Reguła, Kamil Waloch, Andrzej Czajka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 239
Number of citations: 0